ClearPoint Neuro (CLPT) Gross Margin (2011 - 2026)

ClearPoint Neuro has disclosed Gross Margin across 15 years of filings, most recently posting 63.95% for Q1 2026.

• Gross Margin for Q1 2026 came in at 63.95%, up 347.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 62.33% (up 113.0% YoY), and the FY2025 annual result was 61.38%, up 46.0% from the prior year.
• Gross Margin came in at 63.95% for Q1 2026 at ClearPoint Neuro, up from 61.52% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 71.49% in Q3 2022 to a low of 52.54% in Q2 2023.
• The 5-year median for Gross Margin is 61.28% (2024), against an average of 61.39%.
• Across the five-year window, Gross Margin tumbled 1469 bps in 2023 and surged 1094 bps in 2024, its largest moves.
• ClearPoint Neuro's Gross Margin stood at 65.06% in 2022, then fell by 9 bps to 58.93% in 2023, then grew by 4 bps to 61.28% in 2024, then grew by 0 bps to 61.52% in 2025, then increased by 4 bps to 63.95% in 2026.
• The last three Gross Margin figures came in at 63.95% (Q1 2026), 61.52% (Q4 2025), and 63.2% (Q3 2025), per Business Quant data.